Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Enamelon

This article was originally published in The Tan Sheet

Executive Summary

Enamelon: Receives patent for formulation of soluble calcium and phosphate with fluoride as well as for the formulation's application for the remineralization of teeth. Soluble calcium acts in a manner similar to Enamelon's patented "amorphous" calcium formulation/application, the company says: the amorphous calcium changes from solid to liquid form, then recrystallizes once it is deposited in lesions in tooth enamel. The company will begin test marketing products containing the remineralization technology in the first quarter of 1997, followed by a predicted national launch in early 1998 ("The Tan Sheet" July 8, p. 5)...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086371

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel